Compare Honeywell International Inc (HON) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Heron Therapeutics Inc — how do they compare? Honeywell International Inc trades at $208.3 (market cap $65.48B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: Honeywell International Inc is far larger — about 962.8× Heron Therapeutics Inc's market cap, and Honeywell International Inc pays a 1.36% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 91 Days and Heron Therapeutics Inc for 35 Days on average.
| HON | HRTX | |
|---|---|---|
Market Cap | $65.48B | $68.01M |
Volume | 2,047,782 | 1,891,941 |
Sector | Industrials | Health |
52-Week High | $248.79 | $1.49 |
52-Week Low | $188.14 | $0.27 |
Typical Hold Time | 91 Days | 35 Days |
Enterprise Value | $90.27B | $174.75M |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $208.12 with minimal daily movement, showing strong profitability metrics including 21.6% net margin and 47.4% ROE. The company recently completed a strategic split into three focused businesses and secured a $300 million refinery project, positioning for growth in automation. Technical indicators show bearish momentum with support at $205 and resistance at $208, while fundamentals reveal attractive valuation with P/E of 7.9x below industry averages.
HON presents a compelling value opportunity with analyst consensus target of $259.25 representing 25% upside potential. The company's post-spin growth story is gaining momentum with recent earnings beats, though investors should monitor debt levels that have increased to 47.7% of assets and potential execution risks from the corporate restructuring.
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
